The flow of current through the adenosine triphosphate (ATP)-sensitive potassium channel (K ATP ) of the isoform Kir6.2/ SUR1 regulates the resting membrane potential in the pancreatic β-cell. In combination with the cellular glucose metabolism, it is an important minute-to-minute regulator of insulin secretion and whole-body glucose homeostasis. The same K ATP isoform is further reported to be present in glucagon-secreting α-cells, intestinal L-cells, and glucose-responsive neurons in the hypothalamus. All in all, this makes Kir6.2/SUR1 an interesting drug target. Using a commercially available fluorescent membrane potential probe kit and a conventional 96-well fluorescence plate reader, the authors have developed and established qualitative membrane potential assays used to screen for potassium channel closers (KCCs) and openers (KCOs) in insulin-and glucagon-secreting cell lines as well as in cells with recombinant expression of the human Kir6.2/ SUR1 channel complex. Both glucose-and KCC-induced depolarization could be demonstrated. The magnitudes of these responses and KCO-induced repolarization at high glucose displayed some variation between the different cell lines but a similar rank order of test compounds. Some cell types required the presence of a KCC, such as tolbutamide, to display significant effects of KCOs. The authors find that robust and reliable functional in vitro assays compatible with medium-throughput screening and high-throughput screening can be developed as a base for finding new, more potent, and isoform-selective KCCs and KCOs. (Journal of Biomolecular Screening 2004:382-390) Key words: fluorescent membrane potential probe kit, K ATP , Kir6.2/SUR1, potassium channel openers and blockers, HTS, fluorescence plate reader 382 www.sbsonline.org
INTRODUCTION
T HE CURRENT FLOW THROUGH the adenosine triphosphate (ATP)-sensitive potassium channel (K ATP ) of the isoform Kir6.2/SUR1 regulates the resting membrane potential in the pancreatic β-cell. Changes in the glucose concentration outside the βcell are rapidly equilibrated over its plasma membrane through the glucose transporter GLUT2, or GLUT1 in humans. 1 The further metabolism of glucose, through glycolysis and the Krebs cycle, will ultimately affect the ATP and adenosine diphosphate (ADP) concentrations in the cytosol and function as a fuel sensor that can regulate β-cell activity according to the extracellular glucose level. Thus, an increase in extracellular glucose reduces the open probability of the K ATP channels by increasing the ATP/ADP ratio. 2, 3 This is, at glucose levels above basal, followed by depolarization, Ca 2+ influx through opening of the voltage-dependent Ca 2+ channels (VDCCs) of the L type, and exocytosis of insulin-containing granules. 4 When the glucose levels, through the action of insulin released into the bloodstream, return to basal, the ATP/ADP ratio decreases and the K ATP channels open, repolarizing the plasma membrane, closing the VDCCs, and effectively returning the βcells to the resting state. 3 Besides the presence and important function in the pancreatic β-cells, the Kir6.2/SUR1 channel isoform has been reported to be present in glucagon-secreting α-cells, [5] [6] [7] GLP-1-containing intestinal L-cells, 8 and glucose-responsive neurons in the hypothalamus, 9 where its potential importance is yet to be determined. All in all, this makes Kir6.2/SUR1 into an interesting drug target. With regard to the β-cells, isoform-selective potassium channel closers (KCCs) are already used to stimulate insulin secretion in the treatment of type 2 diabetes. 10, 11 Selective potassium channel openers (KCOs) may be used to reduce insulin release in conditions of hypersecretion or to induce β-cell rest. [12] [13] [14] Using a commercially available fluorescent membrane potential probe kit and a conventional fluorescence plate reader, we have developed and established protocols for nonkinetic qualitative membrane potential assays, allowing rapid compound screening in insulin-and glucagon-secreting cell lines as well as in cells with recombinant expression of the human Kir6.2/SUR1 channel complex.
MATERIALS AND METHODS

Materials
All purchased chemicals were of analytical grade. The FLIPR™ membrane potential kit (MPK) (Molecular Devices, Sunnyvale, CA) was bought from GTF (Gothenburg, Sweden).
Diazoxide, BPDZ 73 (7-chloro-3-isopropylamino-4H-1,2,4benzothiadiazine 1,1-dioxide), 15 NNC 55-0118 (6-chloro-3isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide), 16 and NNC 55-0462 (6-chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide) 16 were synthesized in house and kept as 100-mM stock solutions in dry DMSO. Tolbutamide, FCCP (carbonyl cyanide p-[trifluoromethoxy] phenylhydrazone), oligomycin, and antimycin were from Sigma. Black-walled, clear-bottomed 96-well microplates and polypropylene sample plates were from Greiner, Germany.
The NovoStar™ fluorescence plate reader from BMG, Germany, was used for all assay measurements using an excitation filter of 490 ± 5 nm and a long-pass 550-nm emission filter.
Solutions
The solutions used for experiments were the supplemented cell culture media when indicated, trypsin ethylenediaminetetraacetic acid (EDTA; Gibco), and the MPK solutions (loading buffer and Hanks' balanced salt solution [HBSS]; Molecular Devices and Gibco) made according to user instructions, as well as an experimental buffer (KRW) 17 containing (in mM) NaCl 140, KCl 3.6, NaH 2 PO 4 0.5, MgSO 4 0.5, NaHCO 3 2.0, and CaCl 2 1.5, pH 7.4.
The MPK loading buffer contains 2 components: the potential sensitive fluorophore, which is excited at 488 nm and emits around 550 nm, and a quenching dye component that gives the solution a dark black-blue color and is supposed to reduce signal contribution from extracellular fluorophore. The dye mixture is reconstituted in HBSS to make up the final solution.
Cell culture
RPMI 1640 with Glutamax (Gibco), supplemented with 10% fetal calf serum (FCS), 50 µM mercaptoethanol, 100 U/mL penicillin, and 100 µg/mL streptomycin (PEST), was used for the INS-1 cells. 18 Dulbecco's minimal essential medium (DMEM) (Gibco), supplemented with 10% FCS, PEST, and 2 mM glutamine, was used for the βTC3 19 and βTC6 20 as well as αTC1.9 cells. 21 DMEM with supplements as above plus 44 µg/mL hygromycin and 0.6 mg/mL G418 as selection medium was used for the HEK 293 cells with recombinant expression of human Kir6.2/SUR1. 22 All cell lines were cultured at 37°C, 5% CO 2 in humidified air using standard culture ware from Nunc A/S, Denmark.
Experimental
Cells were seeded out in microplates at 50,000 cells/well and cultured for 2 days in a 100-µL/well culture medium. For HEK 293 cells, polylysine-coated plates were used.
On the day of the experiment, the following experimental protocols were used Protocol 1 (wash/add/mix/read):
removal of culture medium and 1 wash in a 200-µL/well KRW buffer without glucose, followed by addition of 160 µL/well KRW + loading buffer (50/50) with 10 mM glucose; incubation for 30 min at 37°C, followed by a baseline measurement and addition of 40 µL/well 5× concentrated test compound dissolved in KRW + loading buffer (50/50) with 10 mM glucose; a second measurement after 10 min or followed dynamically over about 3 min. Protocol 2 (add/mix/read):
direct addition of 100 µL/well of loading buffer with 10 mM glucose; incubation for 30 min at 37°C, followed by a baseline measurement and addition of 50 µL/well 5× concentrated test compound dissolved in KRW + loading buffer (50/50) with 10 mM glucose; a second measurement after 10 min. Protocol 3 (wash/add/mix/read):
as protocol 1, but adapted for monitoring depolarization by omitting glucose in all solutions until after the baseline measurement.
Final DMSO content of well solutions during measurement did not exceed 0.2%.
Confocal microscopy
To investigate the staining properties of the fluorescent probe, NMRI mouse pancreatic islets, prepared and cultured on glass coverslips coated with ECM (as described in Arkhammar et al. 17 ), and βTC3 cells cultured directly on glass coverslips were loaded with the MPK and studied over time at room temperature using a Leica TCS SP Spectral Confocal microscope at 488 nm excitation and 530 to 560 nm emission.
RESULTS
Cellular staining with MPK
Because the molecular identity of the fluorescent membrane potential sensitive probe has not yet been revealed by Molecular Devices, we decided to investigate its intracellular distribution and compare it to a more characterized probe. To do this, we stained cultured primary pancreatic islets as well as βTC3 cells and studied them using confocal fluorescence microscopy. The individual cells stained uniformly in the cytoplasm, whereas the nuclei did not seem to pick up fluorophore (data not shown). The staining patterns were very similar to what has been reported for DiBAC 4 (3)another fluorescent probe for qualitative membrane potential measurements that we have used for screening purposes in βTC3 cells 15 -and more biologically oriented work in an identical islet preparation, 17 so we consider it highly likely that the new fluorophore behaves in a similar fashion as DiBAC 4 (3). A single depolarization experiment using 30 mM KCl in a pancreatic islet also suggested an increase in fluorophore uptake during depolarization without a change in the distribution patterns (data not shown). We found these observations reassuring enough to pursue the study and proceed to a screening format and different cell lines.
Insulin-secreting cell lines assayed for membrane repolarization using KCOs
Establishment of protocol and cell line
The INS-1, βTC3, and βTC6 cell lines were all first tested according to protocol 1. An initial dynamic observation series with INS-1 cells ( Fig. 1 ) revealed a 30% to 40% maximal fluorescence decrease in response to KCOs. The time course for potent compounds such as BPDZ 73 and NNC 55-0462 displayed maximal effects and a fluorescence steady state within a few minutes, whereas diazoxide had slightly slower kinetics. Based on these observations, it was decided to abandon the kinetic mode and do a simplified and more rational protocol, with 1 measurement before addition and a second measurement 5 or 10 min after addition of test compounds. To verify that the presence of 10 mM glucose was enough to close the K ATP channels of the cells, the KCC tolbutamide was included in all test protocols.
As can be seen in Figure 2 , all 3 cell lines were responsive to the test compounds. The dose-response relationships and rank order for all compounds were similar in all 3 lines. The βTC3 line ( Fig.  2A ) was chosen for further studies according to protocol 2 because it gave the largest dynamic change and lowest variation in the responses.
When protocol 2 was run at room temperature versus at 34°C, it was observed that the βTC3 cells displayed a dose-dependent increase in fluorescence in response to tolbutamide and dosedependent decreases in response to the KCOs at room temperature ( Fig. 3A) . At 34°C, the depolarizing effect of tolbutamide disappeared, and the response to the KCOs increased in parallel, suggesting that 10 mM glucose was not sufficient to close all K ATP channels at room temperature (cf. Fig. 3A, B) . A further preincubation of both the 5× concentrated compound plate and cell plate at 34°C in the plate reader ( Fig. 3C ) reduced variation markedly and was incorporated into the final version of protocol 2.
Test for metabolic susceptibility
As described above, it was apparent that the change in glucose metabolism occurring at room temperature compared to 34°C did affect the dynamic range of the assay. In line with this observation, it can be speculated that random screening of compounds will display metabolic toxins as false positives. To substantiate this hypothesis, 3 metabolic blockers with known action were compared with the KCO BPDZ 73. It is shown in Figure 4 that antimycin (an electron transport chain inhibitor), oligomycin (a Fo/F1 ATP synthase inhibitor), and FCCP (a mitochondrial uncoupler [protonophore]) all produced dose responses reminiscent of BPDZ 73. The slopes and maximal effects were similar in all cases. Antimycin and oligomycin were both more potent than BPDZ 73 on a molar basis. . Compounds were added, as indicated by the arrow, with the NovoStar™ injection system, and fluorescence from the individual wells was followed every 10 sec for 2 min. Each curve represents the mean fluorescence value from 3 separate wells.
Assay for repolarization using recombinant expression of human Kir6.2/SUR1 in HEK 293 cells
The stable cell line was tested using protocol 2. It was observed that the effects of KCOs were smaller than in the insulin-producing cells, whereas the effect of tolbutamide was larger, suggesting that the ATP produced by HEK 293 metabolism was not sufficient to close the K ATP channels or that another cellular component of importance for channel closure was missing (data not shown). Tolbutamide was added at various concentrations during the preincubation to test if the channels could be closed using this method (Fig. 5A ). It was found that about 10 µM tolbutamide was enough to achieve full depolarization and that BPDZ 73 still could induce full repolarization in the presence of 10 or 100 µM tolbutamide. Because the inclusion of tolbutamide might affect the potency of KCOs, this was investigated in a separate series of experiments both in the HEK 293 line and the βTC3 cells (Figs. 5B, 6 ). It was found that in βTC3 cells, the presence of 10 µM tolbutamide or less only had marginal effects on the ED 50 of BPDZ 73, NNC 55-0118, and NNC 55-0462, whereas 100 µM tolbutamide rightshifted the ED 50 values of the KCOs by more than an order of magnitude and even completely counteracted the effect of NNC 55-0118 ( Fig. 6) . A similar right-shift was found in the HEK 293 cell line, but it was also noted in both cell lines that the maximal effect 
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of the KCOs was the same at both 10 and 100 µM tolbutamide (Figs. 5A, 6 ). Hence, the HEK 293 assay according to protocol 2 was modified by inclusion of 10 µM tolbutamide from the loading step.
Assay for repolarization in the glucagon-producing cell line TC1.9
The cells were plated out as described above for βTC3 cells and cultured for 2 to 3 days. We used protocol 1 because β-cells normally are depolarized at low glucose concentrations. The KRW was supplemented with 1 mM glucose in this case. As can be seen in Figure 7 , the tested KCOs had repolarizing effects also in this cell line. The magnitudes of the responses were smaller and notably more variable. The overall potency and rank order for the tested KCOs were nevertheless very similar to the findings in the insulinproducing cell lines, supporting the presence of the same K ATP channel isoform in this cell type, as also suggested by others. [5] [6] [7] 
Assay for depolarization in the insulin-producing INS-1 cells
The INS-1 cell line is the only line of the 3 tested that, in our hands, has a robust glucose response with regard to insulin secretion over a more physiological range of glucose concentrations. Using protocol 3, the cells were preincubated 30 min in the absence of glucose and thereafter probed with varying glucose concentrations or tolbutamide. A clear glucose-dependent depolarization with a half-maximal effect at 2 to 3 mM was observed (Fig.  8A ). Using this protocol, the cells were not responsive to the KCO BPDZ 73 but displayed a clear dose response to tolbutamide (Fig.  8B ), suggesting that the K ATP channels were fully open at the beginning of the experiment.
Quality control data for protocol 2 using TC3 and HEK 293 cells expressing human Kir6.2/SUR1
Assay total coefficient of variation (CV) and Z′ values for plate controls were calculated by analyzing an initial run of thirty 96well plates with βTC3 cells (Fig. 9 ). The mean total CV was calculated using the BPDZ 73 serial dilution curves and was 4. was 0.85 ± 0.11 (n = 30). 23 The mean ± SD for the calculated EC 50 values (each EC 50 value based on duplicate or triplicate determinations on the same plate using 8-point dilution series) for the reference compound BPDZ 73 in an extended data set, collected over more than a year, was 0.42 ± 0.19 µM (n = 70). This is a factor 2 to 3 lower than the empirical value observed using the old assay based on the same cells and DiBAC 4 (3), 15 so it is possible that the new assay is slightly more sensitive. With the present assay, we have the same sensitivity cutoff (30% of E max for BPDZ 73) with single-well measurements that we had for quadruplicates with the old assay. Furthermore, it seems like the performance of the present assay is as good as what has been presented for FLIPR™ use with this kit during the Molecular Devices International Products Users Meeting 2003. 24 The same quality control (QC) parameters were calculated for a smaller set of plates of HEK 293 cells. The mean total CV was 5 ± 4, and the mean Z′ was 0.7 ± 0.1 (n = 12). The mean ± SD for the calculated EC 50 values for the reference compound BPDZ 73 was 1.1 ± 0.9 µM (n = 12).
DISCUSSION
The Kir6.2/SUR1 K ATP channel has a central role in the metabolic regulation of β-cell membrane potential and thereby acts as a part of the "glucose sensor" together with glucokinase to modulate insulin secretion in response to changes in the blood sugar concentration. 7 tivity is the cause of the syndrome of persistent hyperinsulinemic hypoglycemia of infancy (PHHI), in which the β-cells are constantly depolarized and intracellular Ca 2+ elevated, leading to a very high basal secretion. 14, 26 A single amino acid polymorphism is found in Kir6.2 in a certain fraction of type 2 diabetics and results in overactivity of the channels, at least in an in vitro system, 27 which may lead to impaired insulin secretion as a consequence. Oversecretion of insulin from insulinomas can usually be treated by a combination of somatostatin and diazoxide. 28, 29 Diazoxide has also been used to "rest" β-cells in newly diagnosed type 1 diabetics and demonstrated a persistent effect in preserving a small fraction of functional β-cells that would have been lost without treatment. 12, 30 However, the use of diazoxide is fraught with side effects, probably due to its low Kir6.2/SUR1 selectivity. Finally, KCCs, such as glibenclamide and the newer repaglinide and formerly tolbutamide, are used clinically to improve the insulin secretory response in type 2 diabetes. 11, 31 To be able to rationally screen for new chemical entities that could be developed into more potent and β-cell-selective KCOs, probably with fewer side effects than diazoxide, we have developed functional assays for membrane repolarization in insulinproducing cell lines. We have previously used a microscopy-based assay with DiBAC 4 (3) as the potential sensitive fluorophore. 15, 17 Due to high background fluorescence from extracellular dye, this assay cannot run in a conventional fluorescence plate reader. In fact, the FLIPR™, which optically reduces the background fluorescence, was developed originally for microplate-based assays using DiBAC 4 (3) . The present membrane potential kit for FLIPR™ comprises an additional technique-extracellular dye quenching-to further reduce contribution from extracellular fluorophore, and we found it interesting to investigate if this new feature would make it possible to go back to a conventional fluorescence plate reader for easier and cheaper compound testing and profiling with increased capacity. We hereby demonstrate that this is indeed the case, and we find that the new assay in βTC3 cells is more sensitive and stable than our old protocol based on DiBAC 4 (3). The insulin-producing lines, such as βTC3, have the clear advantage that their glucose metabolism can be used to maintain a state of metabolic channel closure, but they have the disadvantage of being of rodent origin and having a very long doubling time. The latter fact makes cell culture into a potential bottleneck in a high-throughput screening (HTS) setting. The recombinant human Kir6.2/hSUR1 HEK 293 cells, on the other hand, express the actual target, but the full-channel closure needed to give an acceptable dynamic response can only be achieved by pharmacological means. Fortunately, tolbutamide at a rather low concentration could be used in our cells and did not adversely affect the EC 50 or maximal effect of the tested KCOs. Both of these assays performed in a manner compatible with medium-throughput screening (MTS) and HTS and have proven to give reproducible data over time. Although the βTC3 cell assay gives a better overall performance, the HEK 293 human Kir6.2/hSUR1 assay with tolbutamide present may be preferred, both for having the human target proteins and for, presumably, a reduced metabolic vulnerability.
In conclusion, we have demonstrated that the membrane potential kit from Molecular Devices is suitable for measurements of both qualitative membrane depolarization and repolarization in insulin-and glucagon-producing cells as well as HEK 239 cells with recombinant expression of K ATP channels. The assays can be performed in a conventional fluorescence plate reader, and we suggest temperature control to maintain 34°C and the best dynamic range. All the tested cell lines show robust and prompt responses to reference compounds and good stability with regard to assay protocol, experimental buffer, length of incubations, and temperature. It is evident that compounds that compromise glucose metabolism will give rise to false-positive test results when the cell metabolism per se is used to obtain channel closure. The quality of screening data collected so far is compatible with MTS/HTS.
